An open-label, multi-center, single arm, Proof of Concept, 16-week, Liver Fat Imaging Study of LPCN-1144 to Assess Liver Fat Changes in Hypogonadal Men at Risk of Developing Non-Alcoholic Steatohepatitis (NASH) using MRI-PDFF Technique
Latest Information Update: 12 Sep 2019
At a glance
- Drugs LPCN-1144 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 26 Mar 2019 According to a Lipocine media release, abstract for late-breaker presentation on LPCN 1144 clinical results from this study has been accepted as part of The International Liver Congress 2019, the annual meeting of the European Association for the Study of the Liver (EASL; April 10th-14th in Vienna, Austria)
- 18 Mar 2019 Results presented at the 101st Annual Meeting of the Endocrine Society
- 12 Mar 2019 Status changed from active, no longer recruiting to completed, as reported in a Lipocine Media Release.